Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938201 | 0.87 | AHCY (0.46) | LMNAADORA3CYP2C19 | |
| SCHEMBL6685951 | 0.87 | AHCY (0.46) | LMNAADORA3CYP2C19 | |
| SCHEMBL226038 | 0.86 | ADORA2A (0.43) | LMNAADORA3 | |
| SCHEMBL20798007 | 0.86 | ADORA2A (0.43) | LMNAADORA3 | |
| SCHEMBL6538264 | 0.85 | ADORA2A (0.57) | LMNAADORA3 | |
| Hydrogen Sulfide SCHEMBL28283740 | 0.82 | PI4KA (0.54) | KMT2AADORA3 | |
| Phosphoric Acid SCHEMBL1300003 | 0.81 | RNASEL (0.42) | ADORA3 | |
| SCHEMBL18537398 | 0.81 | PI4KA (0.55) | KMT2AADORA3 | |
| SCHEMBL13061814 | 0.81 | PI4KA (0.55) | KMT2AADORA3 | |
| SCHEMBL16258664 | 0.81 | PI4KA (0.55) | KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364086-B1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8575127-B2 | Antithrombotic diadenosine tetraphosphates and related analogs | GLSYNTHESIS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2364086-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | Glsynthesis Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059215-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GP6, P2RY6, PFKP | BLM 279/4885P2RY1 17/4885P2RY12 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.